Home remote patient management for heart failure,
does it really help with Reduced days lost to unplanned cardiovascular hospitalization or all-cause death?
research showsThe grade is B with 76 points. TIM-HF2 randomized 1,571 patients but analyzed 1,538 who started assigned care: 765 remote-management and 773 usual-care participants. Days lost over one year to unplanned cardiovascular admission or all-cause death were 4.88% versus 6.64%, ratio 0.80 (95% CI 0.65 to 1.00), P=0.046. This corresponded to 17.8 versus 24.2 days per patient-year. It was a large publicly funded trial, but the strategy lacks independent replication.
ads claimOwning connected scales, blood-pressure devices, oximeters, or ECG hardware does not reproduce this evidence. The trial tested a 24-hour physician-led center with protocolized contact and treatment adjustment.
Useful facts when choosing a product
- Weight, blood pressure, heart rate, oxygen saturation, and ECG were transmitted daily for continuous center review.
- NCT01878630 and DRKS00010239 identify the same TIM-HF2 trial.
- The primary set included 1,538 of 1,571 randomized participants, with 31 versus two excluded after not starting care.
What the research actually shows
The 2018 multicenter unmasked trial by Koehler F, Koehler K, Deckwart O, Prescher S, Wegscheider K, Kirwan BA, Winkler S, Vettorazzi E, Bruch L, Oeff M, Zugck C, Doerr G, Naegele H, Störk S, Butter C, Sechtem U, Angermann C, Gola G, Prondzinsky R, Edelmann F, Spethmann S, Schellong SM, Schulze PC, Bauersachs J, Wellge B, Schoebel C, Tajsic M, Dreger H, Anker SD, and Stangl K used secure web randomization for 1,571 patients, 796 versus 775. The full-analysis set included 1,538 who started assigned care, 765 versus 773. The primary result was 4.88% versus 6.64%, ratio 0.80 (0.65 to 1.00), P=0.046. NCT01878630 and DRKS00010239 are two registrations of one TIM-HF2 trial. German Federal Ministry of Education and Research funding, awards 13KQ0904A, 13KQ0904B, and 13KQ1104A, was confirmed.
Why this is classified as B (76)
A large publicly funded randomized trial improved a prespecified endpoint made of actual admission and death events. Single confirmation plus differential post-randomization exclusion gives B with 76 points.
Counterpoint. During the additional year after remote management stopped, the composite difference was no longer present, so claims should distinguish active management from persistence after withdrawal.
Rejudgment record. Cross-check applied — Cross-checked the Lancet report, NCT01878630, and DRKS00010239 for same-trial status, randomized and full-analysis counts, the primary endpoint, secure web allocation, and public funding
| Endpoint | H | Hard endpoint - actual events such as death |
| Replication | R1 | Single confirmatory trial |
| Independence | I2 | Decisive evidence is publicly or non-profit funded |
| Effect size | E+ | Meets the clinically important threshold |
The scoring table and the verdict agree (B).
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Reduced admission-or-death days during remote management | B | 4.88% versus 6.64%, ratio 0.80 (0.65 to 1.00), P=0.046. |
| Persistence for an additional year after remote management stopped | D | Extended follow-up found no difference, ratio 0.97 (0.78 to 1.21). |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Koehler F, Koehler K, Deckwart O, Prescher S, Wegscheider K, Kirwan BA, Winkler S, Vettorazzi E, Bruch L, Oeff M, Zugck C, Doerr G, Naegele H, Störk S, Butter C, Sechtem U, Angermann C, Gola G, Prondzinsky R, Edelmann F, Spethmann S, Schellong SM, Schulze PC, Bauersachs J, Wellge B, Schoebel C, Tajsic M, Dreger H, Anker SD, Stangl K. 2018 | Multicenter parallel-group unmasked trial with secure web randomization | 773 | German Federal Ministry of Education and Research | Percentage of days lost to unplanned cardiovascular hospitalization or all-cause death | 4.88% versus 6.64%, ratio 0.80 (0.65 to 1.00), P=0.046 | Pivotal single large hard-outcome trial |
Receipt — 1 References
All 1 cited sources were verified for existence at the original page (as of 2026-08-15).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-08-15 · Corrections: none
Cite this verdict
[Chamgap] Home remote patient management for heart failure x days lost to cardiovascular hospitalization or death — Evidence Grade B·76. 1 cited sources checked. Source: https://chamgap.com/en/verdicts/heart/heart-failure-structured-remote-patient-management-days-lost/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.